Physician profile
Marcus E Ueltschey
NPI 1447278528
$6,422.80
in general payments reported to CMS, 2019-2025
41 companies · $1,363 in 2025
The $1,363 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $683 · 2020: $367 · 2021: $665 · 2022: $1,027 · 2023: $1,407 · 2024: $912 · 2025: $1,363.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,681.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,680.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $852.21 | 2021-2025 | Vraylar, Ubrelvy, Qulipta |
| Glaxosmithkline, LLC. | $843.96 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $758.62 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $575.53 | 2019-2025 | Jardiance, Synjardy, Ofev |
| Astrazeneca Pharmaceuticals LP | $520.05 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $393.41 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $295.66 | 2020-2025 | Otezla, Repatha, Evenity |
| Pfizer INC. | $277.27 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $247.44 | 2020-2023 | Xifaxan |
| Bausch Health US, LLC | $147.50 | 2020-2023 | Aplenzin |
| Takeda Pharmaceuticals U.S.A., INC. | $143.54 | 2021-2025 | Trintellix |
| Exact Sciences Corporation | $128.00 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Abbott Laboratories | $124.91 | 2023-2025 | Freestyle Libre 3 |
| Amarin Pharma, INC. | $111.19 | 2019-2021 | |
| Esperion Therapeutics, INC. | $93.66 | 2020-2025 | Nexletol |
Show all 41 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Marcus Ueltschey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.